论文部分内容阅读
目的 :探讨肿瘤抗原 12 5 (CA12 5 )与肝硬化腹水的关系 ,评价CA12 5是否可以作为腹水发生的预测指标。方法 :170例患者分为腹水阳性和阴性组 ,分别测定血清CA12 5。结果 :47例腹水阳性病人中有 46例升高 ,占 97 8% ,平均值为 ( 3 2 1± 2 83 )u ml,而腹水阴性组 12 3例 ,只有 9例升高 ,占 7 3 % ,平均值为 ( 13± 15 )u ml,两组比较P <0 0 0 1,9例升高患者平均 1～ 3月内出现腹水。结论 :CA12 5在肝硬化腹水病人中多数呈阳性 ,且与腹水量呈正相关 ,CA12 5升高患者近期内出现腹水 ,说明CA12 5可作为肝硬化出现腹水的预测指标。
Objective: To investigate the relationship between tumor antigen 125 (CA12 5) and cirrhosis ascites and evaluate whether CA12 5 can be used as a predictor of ascites. Methods: One hundred and seventy patients were divided into positive and negative groups of ascites, serum CA12 5 levels were measured. Results: Of the 47 patients with positive ascites, 46 cases were elevated, accounting for 97.8% with an average of (321 ± 2,83) u ml, whereas only 9 of the 37 patients with ascites were negative, accounting for 73% %, Mean (13 ± 15) u ml, the two groups were compared P <0 0 0 1,9 cases of patients with an average of 1 to 3 months of ascites. Conclusion: Most of CA125 in patients with cirrhosis and ascites is positive, and has a positive correlation with the amount of ascites. Ascites appears in patients with elevated CA12 5 in the near future, indicating that CA12 5 can be used as a predictor of ascites in patients with cirrhosis.